Omega-3 fatty acids are among the most extensively studied dietary supplements in cardiovascular medicine. For people with diabetes — who face elevated triglycerides, increased cardiovascular risk, and chronic inflammation — the question of whether omega-3 supplements provide meaningful benefit is both clinically important and surprisingly nuanced.
What Are Omega-3 Fatty Acids?
Omega-3 fatty acids are a family of polyunsaturated fats. The three most clinically relevant forms are eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and alpha-linolenic acid (ALA). EPA and DHA are found primarily in fatty fish (salmon, mackerel, sardines, herring) and in fish oil supplements. ALA is found in plant sources such as flaxseed, chia seeds, and walnuts, but is only partially converted to EPA and DHA in the body — making marine sources far more bioavailable.
What Does the Evidence Show?
Triglyceride reduction: This is the most consistently demonstrated benefit of omega-3 supplementation. High-dose EPA+DHA (2–4 grams per day) reduces triglycerides by 15–30%. This is clinically significant for people with diabetes, who commonly have elevated triglycerides as part of diabetic dyslipidaemia.
Cardiovascular outcomes: The evidence here is more mixed. The REDUCE-IT trial (2018) showed that high-dose icosapentaenoic acid (EPA only, as icosapentaenoic acid ethyl ester — Vascepa) at 4 grams per day reduced major cardiovascular events by 25% in high-risk patients with elevated triglycerides. However, the STRENGTH and ORIGIN trials, using standard fish oil at lower doses, showed no cardiovascular benefit.
Blood glucose: Standard-dose omega-3 supplements do not significantly affect HbA1c or fasting glucose in people with type 2 diabetes. Some early concerns about high-dose fish oil raising blood glucose have not been confirmed in well-controlled trials.
Inflammation: EPA and DHA reduce levels of inflammatory markers including C-reactive protein, interleukin-6, and tumour necrosis factor-alpha. Given that chronic inflammation drives both insulin resistance and cardiovascular disease, this anti-inflammatory effect is clinically relevant even if its direct impact on outcomes is difficult to isolate.
The strongest evidence for omega-3 benefits comes from dietary intake of fatty fish, not supplements. The PREDIMED trial demonstrated that a Mediterranean diet rich in fish and olive oil reduced cardiovascular events by 30% — an effect attributable to the whole dietary pattern, not any single nutrient. Aim for 2–3 servings of fatty fish per week before reaching for a supplement.
Who Should Consider Omega-3 Supplements?
Based on current evidence, omega-3 supplementation is most justified in the following scenarios: triglycerides persistently above 500 mg/dL (where high-dose omega-3s are an established treatment for pancreatitis prevention); triglycerides between 150–499 mg/dL in high cardiovascular risk patients (where high-dose EPA-only preparations like icosapentaenoic acid may be considered); and individuals who cannot or do not eat fatty fish regularly.
- Aim for 2–3 servings of fatty fish per week (salmon, mackerel, sardines)
- If supplementing, choose a product providing at least 1g combined EPA+DHA per day
- For triglyceride reduction, doses of 2–4g EPA+DHA per day are needed
- Look for supplements with third-party purity certification (IFOS or similar)
- Always discuss supplementation with your doctor, especially if on blood thinners
Omega-3 fatty acids offer genuine benefits for triglyceride reduction and inflammation in people with diabetes. However, dietary sources (fatty fish) remain superior to supplements for overall cardiovascular protection. High-dose EPA-only preparations may be appropriate for high-risk patients with persistently elevated triglycerides — discuss this with your care team.
English 
Urdu